oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 10 )

2019 ( 615 )

2018 ( 704 )

2017 ( 697 )

Custom range...

Search Results: 1 - 10 of 401531 matches for " Volpe M "
All listed articles are free for downloading (OA Articles)
Page 1 /401531
Display every page Item
Olmesartan medoxomil for the treatment of hypertension in children and adolescents
Tocci G, Volpe M
Vascular Health and Risk Management , 2011, DOI: http://dx.doi.org/10.2147/VHRM.S11672
Abstract: artan medoxomil for the treatment of hypertension in children and adolescents Review (4465) Total Article Views Authors: Tocci G, Volpe M Published Date March 2011 Volume 2011:7 Pages 177 - 181 DOI: http://dx.doi.org/10.2147/VHRM.S11672 Giuliano Tocci1, Massimo Volpe1,2 1Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Rome; 2IRCCS Neuromed, Pozzilli, Italy Abstract: Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic
Volpe M, Tocci G
Vascular Health and Risk Management , 2012, DOI: http://dx.doi.org/10.2147/VHRM.S28359
Abstract: tionale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic Original Research (2712) Total Article Views Authors: Volpe M, Tocci G Published Date June 2012 Volume 2012:8 Pages 371 - 380 DOI: http://dx.doi.org/10.2147/VHRM.S28359 Received: 18 November 2011 Accepted: 23 December 2011 Published: 11 June 2012 Massimo Volpe,1,2 Giuliano Tocci2 1Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome, Sapienza, Sant'Andrea Hospital, Rome, 2IRCCS Neuromed, Pozzilli, Italy Abstract: Hypertension is a growing global health problem, and is predicted to affect 1.56 billion people by 2025. Treatment remains suboptimal, with control of blood pressure achieved in only 20%–35% of patients, and the majority requiring two or more antihypertensive drugs to achieve recommended blood pressure goals. To improve blood pressure control, the European hypertension guidelines recommend that angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) are combined with calcium channel blockers (CCBs) and/or thiazide diuretics. The rationale for this strategy is based, in part, on their different effects on the renin-angiotensin system, which improves antihypertensive efficacy. Data from a large number of trials support the efficacy of ACEIs or ARBs in combination with CCBs and/or hydrochlorothiazide (HCTZ). Combining two different classes of antihypertensive drugs has an additive effect on lowering of blood pressure, and does not increase adverse events, with the ARBs showing a tolerability advantage over the ACEIs. Among the different ARBs, olmesartan medoxomil is available as a dual fixed-dose combination with either amlodipine or HCTZ, and the increased blood pressure-lowering efficacy of these two combinations is proven. Triple therapy is required in 15%–20% of treated uncontrolled hypertensive patients, with a renin-angiotensin system blocker, CCB, and thiazide diuretic considered to be a rational combination according to the European guidelines. Olmesartan, amlodipine, and HCTZ are available as a triple fixed-dose combination, and significant blood pressure reductions have been observed with this regimen compared with the possible dual combinations. The availability of these fixed-dose combinations should lead to improvement in blood pressure control and aid compliance with long-term therapy, optimizing the management of this chronic condition.
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
Volpe M, Savoia C
Integrated Blood Pressure Control , 2012, DOI: http://dx.doi.org/10.2147/IBPC.S13784
Abstract: reatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil Review (3825) Total Article Views Authors: Volpe M, Savoia C Published Date March 2012 Volume 2012:5 Pages 19 - 25 DOI: http://dx.doi.org/10.2147/IBPC.S13784 Received: 27 December 2011 Accepted: 17 February 2012 Published: 12 March 2012 Massimo Volpe1,2, Carmine Savoia1 1Division of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome Italy; 2IRCCS Neuromed, Pozzilli (Is), Italy Abstract: Renin–angiotensin–system (RAS) activation plays a key role in the development of hypertension and cardiovascular disease. Drugs that antagonize the RAS (angiotensin-converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]) have proven clinical efficacy in reducing blood pressure values and cardiovascular morbidity and mortality. ACE inhibitors partially inhibit plasma ACE, and angiotensin II generation. Thus, ARBs, which block selectively type 1 angiotensin II receptor (AT1R), have been developed and used in the clinical management of hypertension and cardiovascular disease. Experimental and clinical trials with ARBs indicate that this class of drug represents an effective, safe and well tolerated therapeutic option for the prevention and care of hypertension, even though there is no proven superiority as compared to ACE inhibitors except for the better tolerability. Most ARBs may not completely inhibit the AT1R at the approved clinical doses. Azilsartan medoxomil is a newly approved ARB for the management of hypertension. This ARB induces a potent and long-lasting antihypertensive effect and may have cardioprotective properties. This article reviews the current evidence on the clinical effectiveness of azilsartan in hypertension.
Olmesartan medoxomil for the treatment of hypertension in children and adolescents
Tocci G,Volpe M
Vascular Health and Risk Management , 2011,
Abstract: Giuliano Tocci1, Massimo Volpe1,21Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Rome; 2IRCCS Neuromed, Pozzilli, ItalyAbstract: Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.Keywords: hypertension, high blood pressure, children, adolescents, antihypertensive treatment, olmesartan medoxomil
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic
Volpe M,Tocci G
Vascular Health and Risk Management , 2012,
Abstract: Massimo Volpe,1,2 Giuliano Tocci21Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome, Sapienza, Sant'Andrea Hospital, Rome, 2IRCCS Neuromed, Pozzilli, ItalyAbstract: Hypertension is a growing global health problem, and is predicted to affect 1.56 billion people by 2025. Treatment remains suboptimal, with control of blood pressure achieved in only 20%–35% of patients, and the majority requiring two or more antihypertensive drugs to achieve recommended blood pressure goals. To improve blood pressure control, the European hypertension guidelines recommend that angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) are combined with calcium channel blockers (CCBs) and/or thiazide diuretics. The rationale for this strategy is based, in part, on their different effects on the renin-angiotensin system, which improves antihypertensive efficacy. Data from a large number of trials support the efficacy of ACEIs or ARBs in combination with CCBs and/or hydrochlorothiazide (HCTZ). Combining two different classes of antihypertensive drugs has an additive effect on lowering of blood pressure, and does not increase adverse events, with the ARBs showing a tolerability advantage over the ACEIs. Among the different ARBs, olmesartan medoxomil is available as a dual fixed-dose combination with either amlodipine or HCTZ, and the increased blood pressure-lowering efficacy of these two combinations is proven. Triple therapy is required in 15%–20% of treated uncontrolled hypertensive patients, with a renin-angiotensin system blocker, CCB, and thiazide diuretic considered to be a rational combination according to the European guidelines. Olmesartan, amlodipine, and HCTZ are available as a triple fixed-dose combination, and significant blood pressure reductions have been observed with this regimen compared with the possible dual combinations. The availability of these fixed-dose combinations should lead to improvement in blood pressure control and aid compliance with long-term therapy, optimizing the management of this chronic condition.Keywords: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, triple therapy, hypertension
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
Volpe M,Savoia C
Integrated Blood Pressure Control , 2012,
Abstract: Massimo Volpe1,2, Carmine Savoia11Division of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome Italy; 2IRCCS Neuromed, Pozzilli (Is), ItalyAbstract: Renin–angiotensin–system (RAS) activation plays a key role in the development of hypertension and cardiovascular disease. Drugs that antagonize the RAS (angiotensin-converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]) have proven clinical efficacy in reducing blood pressure values and cardiovascular morbidity and mortality. ACE inhibitors partially inhibit plasma ACE, and angiotensin II generation. Thus, ARBs, which block selectively type 1 angiotensin II receptor (AT1R), have been developed and used in the clinical management of hypertension and cardiovascular disease. Experimental and clinical trials with ARBs indicate that this class of drug represents an effective, safe and well tolerated therapeutic option for the prevention and care of hypertension, even though there is no proven superiority as compared to ACE inhibitors except for the better tolerability. Most ARBs may not completely inhibit the AT1R at the approved clinical doses. Azilsartan medoxomil is a newly approved ARB for the management of hypertension. This ARB induces a potent and long-lasting antihypertensive effect and may have cardioprotective properties. This article reviews the current evidence on the clinical effectiveness of azilsartan in hypertension.Keywords: RAS, sartan, hypertension, cardiovascular protection
Short-term VHE variability in blazars: PKS 2155-304
Frank M. Rieger,Francesca Volpe
Physics , 2010, DOI: 10.1051/0004-6361/201014273
Abstract: Context: The $\gamma$-ray blazar PKS 2155-304 has attracted considerable attention because of its extreme TeV variability characteristics during an exceptional flaring period in 2006. Among the observed key findings are (i) a minimum variability timescale as short as $\sim 200$ sec and (ii) highly variable TeV emission, which in the frequency interval [$10^{-4}$ Hz, $10^{-2}$ Hz] can be described by a log-normal distribution and suggests an underlying multiplicative (and not additive) process. Aims: Simultaneously accounting for these findings appears difficult within conventional approaches. Following earlier suggestions for the TeV blazar Mkn 501, we explore a possible scenario where PKS 2155-304 is supposed to harbor a supermassive binary black hole system and where the observed TeV variability is dominated by emission from the less massive black hole. Methods: We analyze the constraints on the very high energy (VHE) source imposed by the observed variability characteristics and the integrated VHE luminosity output, and discuss its implications for a binary black hole system. Results: We show that for a secondary mass of $m_{\rm BH} \sim 10^7 M_{\odot}$, fluctuations in the disk accretion rate that feed the jet could account for the observed red-noise type variability process down to frequencies of $\sim 10^{-2}$ Hz. Jet curvature induced by orbital motion, on the other hand, could further relax constraints on the intrinsic jet speeds. Conclusions: Because a binary system can lead to different (yet not independent) periodicities in different energy bands, a longterm (quasi-) periodicity analysis could offer important insights into the real nature of the central engine of PKS~2155-304.
Rapid VHE variability in blazars
Francesca Volpe,Frank M. Rieger
Physics , 2011,
Abstract: Active Galactic Nuclei (AGN) are known to show significant variability over a wide frequency range. We review observational results on the variability characteristics of blazars in the very high energy (VHE) domain, focusing on recent findings of rapid VHE variability and evidence for an underlying multiplicative driving process in PKS 2155-304. We explore a physical scenario where the variability is assumed to arise due to accretion disk fluctuations transmitted to the jet, and discuss its implications for the central powerhouse.
A Theoretical Overview of Bioresponse to Magnetic Fields on the Earth’s Surface  [PDF]
Pietro Volpe
International Journal of Geosciences (IJG) , 2014, DOI: 10.4236/ijg.2014.510097
Abstract: This survey points to the mechanisms of bioresponse caused by magnetic fields (MFs), paying attention to their action not only on ions, molecules and macromolecules, but also on cells, tissues and organisms. The significance of findings concerning the MF-dependence of cell proliferation, necrosis or apoptosis was judged by comparing the results obtained in a solenoid, where an MF can be added to the geomagnetic field (GMF), with those obtained in a magnetically shielded room, where the MFs can be attenuated or null. This comparative criterion was particularly appropriate when the differences detectable between the data provided by experimental samples and the data provided by control samples were rather small, as observed in estimating the MF-influence on total DNA replication, RNA transcription and polypeptide translation. The MF-induced inhibition of apoptosis was considered as a risk potentially leading to accumulation of cancer cells. The analysis also surveyed the MF-dependence of the interactions between host animal cells and infecting bacteria. In relation to studies on the origin and adaptation of life on the Earth, theoretical insights paving the way to elucidating the MF-interactions with biostructures and biosystems of different orders of organization evaluated the possible involvement of the so-called “biological windows”. Analogously to what is known for ionizing radiations, the efficiency of the applied MFs appeared to depend on the complexity of their biological targets.
The Unexpected Existence of Coding and Non-Coding Fragments along the Eukaryotic Gene  [PDF]
Pietro Volpe
Advances in Biological Chemistry (ABC) , 2015, DOI: 10.4236/abc.2015.52009
Abstract: The pathways leading to synthesis and post-synthetic modification of DNA employed methionine as donor of atoms: the carbon that came from its –CH3 served for DNA replication and repair either in bacteria or humans; its entire –CH3 served instead for building N6-methyladenine and 5-methylcytosine on bacterial DNA and 5-methylcytosine alone on human DNA. In humans, although a slight extra-S asymmetric methylation appeared de novo yielding on parental DNA 5’-m5CpC-3’/ 3’-GpG-5’, 5’-m5CpT-3’/3’-GpA-5’ and 5’-m5CpA-3’/3’-GpT-5’ monomethylated dinucleotide pairs, a heavy symmetric methylation involved in S semiconservatively newly made DNA to guarantee genetic maintenance of –CH3 in 5’-m5CpG-3’/3’-Gpm5C-5’ dimethylated dinucleotide pairs. In this framework, an inverse correlation was found between bulk genomic DNA methylation occurring in S and bulk polyA-containing pre-mRNA transcription taking place in G1 and G2. Thus, probes of 1 × 106 Daltons (constructed using sheared by sonication newly made methylated DNA filaments) revealed a modular organization in genes: after the hypermethylated promoter, they exhibited an alternation of unmethylated coding and methylated uncoding sequences. This encouraged the search for a language that genes regulated by methylation should have in common. An initial deciphering of restriction minimaps with hypomethylatable exons vs. hypermethylatable promoters and introns was improved when the bisulfite technique allowed a direct sequencing of m5C. In lymphocytes, where the transglutaminase gene is inactive, its promoter exhibited two fully methylated CpG-rich domains at 5’ and one fully unmethylated CpG-rich domain at 3’, including the site +1 and a 5’-UTR. At variance, in HUVEC cells, where the transglutaminase gene is active, in the first CpG-rich domain of promoter few doublets lost their –CH3. Such an inverse correlation suggested new hypotheses especially in connection with repair-modification: UV radiation would cause demethylation in given loci of a promoter by chance, whilst even a partial demethylation in this promoter would be able to resume a previously silent pre-mRNA transcription.
Page 1 /401531
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.